For the quarter ending 2026-03-31, ENSC had -$3,564,872 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -3,556,415 | -2,767,969 | -3,729,128 | -3,679,090 |
| Accrued interest | 3,089 | 3,125 | 3,161 | 6,107 |
| Change in fair value of liability classified warrants | - | 35 | 998 | 9,063 |
| Consultant compensation | - | 414,951 | 50,717 | 203,014 |
| Stock-based compensation | 8,743 | 24,339 | 45,858 | 106,889 |
| Amortization of orginal issue discount and debt issuance costs | - | - | - | 0 |
| Depreciation expense | 6,533 | 6,533 | - | - |
| Unbilled receivable | -420,345 | 415,934 | -1,200,568 | 1,080,864 |
| Prepaid expenses and other assets | -1,292,926 | 1,219,459 | -779,709 | -1,185 |
| Accounts payable | -1,663,513 | 2,709,279 | -579,374 | -314,247 |
| Accrued expenses and other liabilities | -12,633 | -280,663 | 363,308 | 351,789 |
| Net cash used in operating activities | -3,500,925 | -1,525,833 | -1,866,179 | -4,414,280 |
| Investment in property and equipment | - | 0 | 123,643 | - |
| Net cash flows used in investing activities | - | 0 | -123,643 | - |
| Repayment of convertible notes | - | - | - | 0 |
| Proceeds from public offerings | - | 0 | 0 | 1,100,007 |
| Proceeds from warrant exercises | - | 684,358 | 1,496,854 | 390,855 |
| Proceeds from warrant inducement, net of issuance costs | - | 0 | 0 | 2,200,012 |
| Transaction costs from public offerings | - | - | 0 | 204,193 |
| Proceeds from issuance of series b preferred stock | - | 3,975,000 | - | - |
| Transaction costs associated with public offering and warrant inducements | - | 204,193 | 5,410 | 291,611 |
| Transaction costs associated with series b preferred stock issuance | - | 391,376 | - | - |
| Repayment of financed insurance premiums | 63,947 | 105,013 | 39,979 | 71,292 |
| Net cash (used in) provided by financing activities | -63,947 | 4,162,969 | 1,451,465 | 3,123,778 |
| Decrease in cash and cash equivalents | -3,564,872 | 2,637,136 | -538,357 | -1,290,502 |
| Cash and cash equivalents beginning of period | 4,310,354 | 1,673,218 | 3,502,077 | - |
| Cash and cash equivalents end of period | 745,482 | 4,310,354 | 1,673,218 | - |
Ensysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc. (ENSC)